SMARCA4 and non-small cell lung carcinoma: We found that NSCLC patients with homozygous, truncating SMARCA4 mutations had significantly reduced overall survival (OS) compared to the wildtype (WT) SMARCA4 cohort (HR 1.85, P < 0.0001) (Fig. 2c).